TY - JOUR
T1 - The landscape of viral associations in human cancers
AU - Zapatka, Marc
AU - Borozan, Ivan
AU - Brewer, Daniel S.
AU - Iskar, Murat
AU - Grundhoff, Adam
AU - Alawi, Malik
AU - Desai, Nikita
AU - Sültmann, Holger
AU - Moch, Holger
AU - Cooper, Colin S.
AU - Eils, Roland
AU - Ferretti, Vincent
AU - Lichter, Peter
AU - Kleinheinz, Kortine
AU - Nakagawa, Hidewaki
AU - Ojesina, Akinyemi I.
AU - Pedamallu, Chandra Sekhar
AU - Schlesner, Matthias
AU - Xiaoping, Su
AU - Aaltonen, Lauri A.
AU - Abascal, Federico
AU - Abeshouse, Adam
AU - Aburatani, Hiroyuki
AU - Adams, David J.
AU - Agrawal, Nishant
AU - Ahn, Keun Soo
AU - Ahn, Sung Min
AU - Aikata, Hiroshi
AU - Akbani, Rehan
AU - Akdemir, Kadir C.
AU - Al-Ahmadie, Hikmat
AU - Al-Sedairy, Sultan T.
AU - Al-Shahrour, Fatima
AU - Albert, Monique
AU - Aldape, Kenneth
AU - Alexandrov, Ludmil B.
AU - Ally, Adrian
AU - Alsop, Kathryn
AU - Alvarez, Eva G.
AU - Amary, Fernanda
AU - Amin, Samirkumar B.
AU - Aminou, Brice
AU - Ammerpohl, Ole
AU - Anderson, Matthew J.
AU - Ang, Yeng
AU - Antonello, Davide
AU - Anur, Pavana
AU - Aparicio, Samuel
AU - Appelbaum, Elizabeth L.
AU - Pritchard, Antonia L.
N1 - © 2020, The Author(s). Published by SpringerNature. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
PY - 2020/2/5
Y1 - 2020/2/5
N2 - Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, for which whole-genome and—for a subset—whole-transcriptome sequencing data from 2,658 cancers across 38 tumor types was aggregated, we systematically investigated potential viral pathogens using a consensus approach that integrated three independent pipelines. Viruses were detected in 382 genome and 68 transcriptome datasets. We found a high prevalence of known tumor-associated viruses such as Epstein–Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for example, HPV16 or HPV18). The study revealed significant exclusivity of HPV and driver mutations in head-and-neck cancer and the association of HPV with APOBEC mutational signatures, which suggests that impaired antiviral defense is a driving force in cervical, bladder and head-and-neck carcinoma. For HBV, HPV16, HPV18 and adeno-associated virus-2 (AAV2), viral integration was associated with local variations in genomic copy numbers. Integrations at the TERT promoter were associated with high telomerase expression evidently activating this tumor-driving process. High levels of endogenous retrovirus (ERV1) expression were linked to a worse survival outcome in patients with kidney cancer.
AB - Here, as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, for which whole-genome and—for a subset—whole-transcriptome sequencing data from 2,658 cancers across 38 tumor types was aggregated, we systematically investigated potential viral pathogens using a consensus approach that integrated three independent pipelines. Viruses were detected in 382 genome and 68 transcriptome datasets. We found a high prevalence of known tumor-associated viruses such as Epstein–Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV; for example, HPV16 or HPV18). The study revealed significant exclusivity of HPV and driver mutations in head-and-neck cancer and the association of HPV with APOBEC mutational signatures, which suggests that impaired antiviral defense is a driving force in cervical, bladder and head-and-neck carcinoma. For HBV, HPV16, HPV18 and adeno-associated virus-2 (AAV2), viral integration was associated with local variations in genomic copy numbers. Integrations at the TERT promoter were associated with high telomerase expression evidently activating this tumor-driving process. High levels of endogenous retrovirus (ERV1) expression were linked to a worse survival outcome in patients with kidney cancer.
UR - https://www.scopus.com/pages/publications/85079063026
UR - https://www.scopus.com/pages/publications/85079063026#tab=citedBy
U2 - 10.1038/s41588-019-0558-9
DO - 10.1038/s41588-019-0558-9
M3 - Article
C2 - 32025001
AN - SCOPUS:85079063026
SN - 1061-4036
VL - 52
SP - 320
EP - 330
JO - Nature Genetics
JF - Nature Genetics
IS - 3
ER -